The question here is: would you prefer to work your behind off every day for $100hr or sit on a beach while 10 entities license something of yours that nets you $10hr each? Or maybe, just maybe, a little of both?
The point is . . . this is not being brought to market by INSM . . . it is not INSM's program of development . . . it was out licensed by Transave before the merger. Total misrepresentation of the impact on INSM in the future. The entire Iplex out license for ROP was a net $11.5 million. If INSM ever sees one tenth of that from the cisplatin liposome in the next 10 years, that would be the best that any investor could hope for. Cancer drugs currently take 14 years to get through the regulatory maze.